Bausch + Lomb Corporation announced that Chief Executive Officer Brent Saunders and the Board mutually agreed to his departure, effective October 12, 2026. Saunders will cease serving on the Board and forfeit all outstanding equity awards. In connection with the separation, he receives a lump-sum cash payment of $75.5 million plus up to $50,000 in legal fee reimbursement. Thomas J. Appio, Chairman of the Board and CEO of controlling shareholder Bausch Health Companies Inc., was appointed interim Chief Executive Officer effective immediately. The company also disclosed that it expects to raise full-year 2026 adjusted EBITDA guidance based on preliminary third-quarter results. Bausch + Lomb Corporation is a leading global eye health company developing, manufacturing, and marketing contact lenses, prescription products, surgical devices, and over-the-counter options.
